Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results